Adolfo Favaretto

TL;DR: Vinorelbine improves survival of elderly patients with advanced NSCLC and possibly improves overall quality of life (QoL) in a multicenter randomized trial that compared vinore lbine treatment with supportive care alone.

TL;DR: Although quality of life was similar across the three treatment arms, the combination treatment was more toxic than the two drugs given singly and not more effective than single-agent vinorelbine or gemcitabine in the treatment of elderly patients with advanced NSCLC.

TL;DR: In this article, the prognostic value for overall survival of baseline assessment of functional status, comorbidity, and quality of life (QoL) in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy was studied.

TL;DR: Subjective toxicities are at high risk of under-reporting by physicians, even when prospectively collected within randomized trials, and this strongly supports the incorporation of patient-reported outcomes into toxicity reporting in clinical trials.

TL;DR: Disease control rate, time to disease progression, and overall survival were similar to the results achieved with the standard regimen of pemetrexed and cisplatin, suggesting that the carboplatin combination could be an alternative option for these patients.